Codexis Inc Dossier
Qualitative Analysis
Business overview
Codexis, Inc. (NASDAQ: CDXS) is a leading biotechnology company specializing in the development of high-performance enzyme-based technology solutions to optimize pharmaceutical manufacturing processes. The company operates through two primary business areas: the ECO Synthesis™ manufacturing platform and its established small molecule pharma biocatalysis business. The ECO Synthesis™ platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference (RNAi) therapeutics, aiming to revolutionize manufacturing processes in this high-growth market. The biocatalysis business utilizes engineered enzymes developed via its proprietary CodeEvolver® technology platform to enhance efficiency, yield, and sustainability in small molecule drug manufacturing.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting from technology development to commercial execution by driving orders for the ECO Synthesis platform, which enables scalable enzymatic manufacturing of RNAi therapeutics (siRNA).
Expected impact: Positions Codexis as a leading supplier in the $2 billion annual siRNA production technology market.
Retrofitting the Hayward, California facility to establish in-house GMP manufacturing capabilities for clinical-grade siRNA material.
Expected impact: Enables Codexis to support customers from preclinical development through clinical trials and commercial launch.
Executing workforce realignments and operational streamlining to reduce annual cash burn and extend the cash runway.
Expected impact: Extends the company's cash runway through the end of 2027, covering key milestones for the ECO Synthesis platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Validates Codexis' enzyme engineering platform and provides significant non-dilutive capital to fund operations.
Terms: $37.8 million technology transfer agreement executed in Q4 2025, with minor revenue contributions continuing into 2026.
Establishes a commercial ecosystem for the ECO Synthesis platform, allowing leading CDMOs to showcase and utilize Codexis' ligase technology.
Terms: Individual commercial terms not fully disclosed; agreements focus on scaling and marketing enzymatic RNA synthesis.